Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $93.27 USD
Change Today -0.81 / -0.86%
Volume 997.8K
ENDP On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Ivan P. Gergel M.D.

Former Chief Scientific Officer and Executive Vice President of Research & Development, Endo International plc
AgeTotal Calculated CompensationThis person is connected to 47 board members in 4 different organizations across 7 different industries.

See Board Relationships
53--
As of Fiscal Year 2013

Background*

Dr. Ivan P. Gergel, M.D., has been the Chief Medical Officer and Senior Vice President of Drug Development at Nektar Therapeutics since May 19, 2014. Dr. Gergel has more than 25 years of pharmaceutical leadership and drug development experience. He served as the Chief Scientific Officer and Executive Vice President of Research & Development at Endo International Plc, Endo Health Solutions Inc. and Endo Pharmaceuticals Solutions Inc. from April 29, 2008 to March 31, 2014, ...

Read Full Background

Corporate Headquarters*

Minerva House
Dublin, Co. Dublin 4

Ireland

Phone: 353 1 268 2000
Fax: --

Board Members Memberships*

Director
2009-N/A
Executive Vice President of Research & Development
2010-Present
Director
2010-Present
Director
2014-Present
Director and Member of Technology & Product Development Committee

Education*

MBA
University of Pennsylvania - The Wharton School
MD
Royal Free and University College Medical School

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENDP:US $93.27 USD -0.81

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael W. Aguiar Chief Executive Officer, President and Director
Theravance Inc.
$557.2K
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
$100.0K
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
$620.1K
Peter S. Greenleaf Chief Executive Officer and Director
Sucampo Pharmaceuticals, Inc.
$440.2K
Daniel J. Abdun-Nabi Chief Executive Officer, President, Director, Member of Strategic Operations Committee and Member of Pricing Committee
Emergent BioSolutions, Inc.
$1.2M
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDO INTERNATIONAL PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.